Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and 18F-FDG-PET/CT: Correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade

Journal of Magnetic Resonance Imaging

Volumn 40, Issue 5, 2014, Pages 1147-1157

  Giganti, Francesco ^a   De Cobelli, Francesco ^a   Canevari, Carla ^b,c   Orsenigo, Elena ^a   Gallivanone, Francesca ^c   Esposito, Antonio ^a   Castiglioni, Isabella ^c   Ambrosi, Alessandro ^a   Albarello, Luca ^b   Mazza, Elena ^b   Gianolli, Luigi ^b   Staudacher, Carlo ^a   Del Maschio, Alessandro ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

ADC; DW MRI; Gastric cancer; PET MRI; PVC SUVBW mean; TRG

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOBUTROL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTIAL VOLUME CORRECTED STANDARDIZED UPTAKE VALUE; PREOPERATIVE TREATMENT; RADIOLOGICAL PARAMETERS; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; TUMOR REGRESSION; ADENOCARCINOMA; ADJUVANT THERAPY; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; GASTRECTOMY; IMAGE ENHANCEMENT; MULTIMODAL IMAGING; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSPECTIVE STUDY; STATISTICS; STOMACH; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; GASTRECTOMY; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; STOMACH; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84913613051     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24464     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159- 167.
3. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (abstract). J Clin Oncol 2007;25:4510.
4. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210-5218.
5. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
6. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25:2107-2116.
7. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530.
8. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229: 303-308.
9. Garcia C, Gebhart G, Flamen P. New PET imaging agents in the management of solid cancers. Curr Opin Oncol 2012;24: 748-755.
10. Kalia M. Personalized oncology: recent advances and future challenges. Metabolism 2013;62(Suppl 1):S11-S14.
11. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000;27: 647-655.
12. Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori T, Okazawa H. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 2013;54:499-506.
13. Gallivanone F, Stefano A, Canevari C, et al. 18F-FDG relationship with histopathological and immunoistochemical data in breast cancer using SUV with or without partial volume correction. Eur J Nucl Med Mol Imaging 2011;38(Suppl 2):S277.
14. Byun BH, Kong CB, Lim I, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med 2013;54:1053-1059.
15. Gallivanone F, Stefano A, Grosso E, et al. PVE correction in PETCT whole body oncological studies from PVE-affected images. IEEE Trans Nucl Sci 2011;58:736-747.
16. Lutz MP, Zalcberg JR, Ducreux M, et al. Highlights of the EORTC St. Gallen International Export Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012;48:2941-2953.
17. Takebayashi R, Izuishi K, Yamamoto Y, et al. [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer. J Exp Clin Cancer Res 2013;32:34.
18. Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer 2011;14:13-21.
19. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008;14:2012-2018.
20. Hein PA, Kremser C, Judmaier W, et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003;45: 214-222.
21. Kim SH, Lee JY, Lee JM, Han JK, Choi BI. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 2011;21:987-995.
22. De Cobelli F, Giganti F, Orsenigo E, et al. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur Radiol 2013;23:2165-2174.
23. Gu J, Khong PL, Wang S, Chan Q, Law W, Zhang J. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol 2011;13:1020-1028.
24. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficient measured by 3T diffusionweighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 2009;36:200-208.
25. Tang L, Zhang XP, Sun YS, et al. Gastrointestinal stromal tumors treated with Imatinib Mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. Radiology 2011; 258:729-738.
26. Gong NJ, Wong CS, Chu YC, Gu J. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography. NMR Biomed 2013;26:185-192.
27. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma Clinicopathologic correlations. Cancer 1994;73:2680-2686.
28. Hermann RM, Horstmann O, Haller F, et al. Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use? Dis Esophagus 2006;19:329-334.
29. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752-760.
30. Bettinardi V, Danna M, Savi A, et al. Performance evaluation of the new whole-body PET/CT scanner: Discovery ST. Eur J Nucl Med Mol Imaging 2004;31:867-881.
31. Bettinardi V, Mancosu P, Danna M, et al. Two-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study. Q J Nucl Med Mol Imaging 2007;51:214-223.
32. Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET=CT Discovery- 690. Med Phys 2011;38:5394-5411.
33. Sathiakumar C, Som S, Eberl S, Lin P. NEMA NU 2-2001 performance testing of a Philips Gemini GXL PET/CT scanner. Australas Phys Eng Sci Med 2010;33:199-209.
34. Davison AC, Hinkley DV, Young GA. Recent developments in bootstrap methodology. Stat Sci 2003;18:141-157.
35. Zou KH, Hall WJ, Shapiro DE. Smooth non-parametric receiver operating characteristic (ROC) curves for continuous diagnostic tests. Stat Med 1997;16:2143-2156.
36. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
37. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med 2008;49:43S-63S.
38. Lichy MP, Aschoff P, Plathow C, et al. Tumor detection by diffusion-weighted MRI and ADC-mapping - initial clinical experiences in comparison to PET-CT. Invest Radiol 2007;42:605-613.
39. Heijmen L, Verstappen MC, Ter Voert EE, et al. Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol Hematol 2012;83:194-207.
40. Di Fabio F, Pinto C, Rojas Llimpe, et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007;10:221-227.
41. Lim JS, Yun MJ, Kim MJ, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006;26:143-156.
42. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-945.
43. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-908.
44. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776- 1785.
45. Konski AA, Cheng JD, Goldberg M, et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:358-363.
46. Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2013;258:66-76.
47. Weber MA, Bender K, von Gall CC, et al. Assessment of diffusionweighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction. J Gastrointest Liver Dis 2013;22:45-52.
48. Vallbohmer D, Holscher AH, Schneider PM, et al. [18F]-fluorodeoxyglucose- positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010; 102:135-140.
49. Yang QM, Bando E, Kawamura T, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Jpn J Cancer Chemother 2006;33:1817-1821.
50. Suttie SA, Welch AE, Park KG. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. Eur J Surg Oncol 2009;35:1019-1029.
51. Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology 2013;267: 26-44.